The FDA has approved Avodart (dutasteride, from GlaxoSmithKline) in combination with Flomax (tamsulosin, from Boehringer Ingelheim) for the treatment of symptomatic benign prostatic hyperplasia (BPH). This approval was based on results from the CombAT study which showed that Avodart and Flomax combination therapy was superior to both monotherapies at month 12 and continued to month 24 when measured by changes from baseline under the International Prostate Symptom Score (IPSS).

Avodart is already indicated as monotherapy for the treatment of BPH to improve urinary symptoms and reduce the risk of acute urinary retention (AUR) and need for prostate surgery.

For more information call (888) 825-5249 or visit www.avodart.com.